Biotech RadarJobs updated

COMPANY

REGENXBIO Inc.

HQ: Rockville, MD source · regenxbio.com ↗ · Mid-Atlantic

Clinical Phase 3

Also known as ReGenX Biosciences, Regenxbio · 11 open jobs · last seen Oct 23, 2026 · 22 sources

Keywords: gene therapy ophthalmology retinal diseases AAV Mucopolysaccharidosis II Duchenne Muscular Dystrophy Homozygous Familial Hypercholesterolemia Mucopolysaccharidosis Type II MPS II Hunter Syndrome (MPS II) Mucopolysaccharidosis I Mucopolysaccharidosis Type I Hurler Syndrome Hurler-Scheie Syndrome Neovascular Age-related Macular Degeneration Wet Age-related Macular Degeneration Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) Late-infantile Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) RGX-202 RGX-121 RGX-121-3102 RGX-111 AAV directed hLDLR gene therapy RGX-314

Profile checked Oct 10, 2026

Since the raise (Jul 17, 2026): 11 of 11 open jobs were first seen after it.

11Open jobs$100.0MRaised (2 yrs)18Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
VP, Global Rare Disease FranchiseRemoteOct 1, 2026Oct 8, 2026
Vice President, Information TechnologyRockville, MarylandOct 1, 2026Oct 8, 2026
People InternRockville, MarylandSep 30, 2026Oct 8, 2026
Associate Director, Regulatory AffairsRockville, MarylandSep 29, 2026Oct 8, 2026
Head of Sales, Rare DiseaseRemoteSep 29, 2026Oct 8, 2026

See all 11 jobs

Trial and FDA signals

Job counts as of Oct 18, 2026. All trial and FDA signals

Timeline

  1. Board tracked Radar started tracking this company’s job board (11 open jobs at last check). source ↗
  2. Raise Follow-on offering: $100M (total, as published), announced Jul 17, 2026. Source: SEC filing. source ↗
  3. Trial start Phase 3: RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome) source ↗
  4. Debt Debt financing: $250M (up to, as announced), announced May 19, 2025. Source: SEC filing. source ↗
  5. Partnership Partnership / licensing announced Mar 4, 2025. Source: SEC filing. source ↗
  6. Partnership Partnership / licensing: $110M (upfront, as published); deal value up to $700M (kept separate from upfront), announced Jan 14, 2025. Source: SEC filing. source ↗
  7. Trial start —: Long Term Follow-up for RGX-202 source ↗
  8. Trial start —: Long Term Follow-Up for RGX-111 source ↗
  9. Trial start Phase 2/Phase 3: AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD) source ↗
  10. Trial start —: AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Males With DMD source ↗
  11. Trial start —: Mucopolysaccharidosis Type II Observational source ↗
  12. Trial start —: An Observational Study in Children With CLN2 Batten Disease source ↗
  13. Trial start —: A Retrospective, Natural History Study in Children With CLN2 source ↗
  14. Trial start —: Long-term Follow-Up for RGX-121 source ↗
  15. Trial start Phase 1/Phase 2: RGX-121 Gene Therapy in Children 5 Years of Age and Over With MPS II (Hunter Syndrome) source ↗
  16. Trial start —: Identifying and Genotyping Homozygous Familial Hypercholesterolemia (HoFH) Patients source ↗
  17. Trial start —: A Long-term Follow-up Study to Evaluate the Safety and Efficacy of RGX-501 source ↗
  18. Trial start Phase 1/Phase 2: RGX-111 Gene Therapy in Patients With MPS I source ↗
  19. Trial start Phase 2/Phase 3: CAMPSIITE™ RGX-121 Gene Therapy in Subjects With MPS II (Hunter Syndrome) source ↗
  20. Trial start —: Mucopolysaccharidosis Type II Natural History source ↗
  21. Trial start Phase 1/Phase 2: Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial source ↗
  22. Trial start Phase 1/Phase 2: A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH) source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 11

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
VP, Global Rare Disease FranchiseRemoteOct 1, 2026Oct 8, 2026Executive
Vice President, Information TechnologyRockville, MarylandOct 1, 2026Oct 8, 2026Executive
People InternRockville, MarylandSep 30, 2026Oct 8, 2026Entry
Associate Director, Regulatory AffairsRockville, MarylandSep 29, 2026Oct 8, 2026Senior
Head of Sales, Rare DiseaseRemoteSep 29, 2026Oct 8, 2026Executive
Associate Director, People Business PartnerRockville, MarylandSep 14, 2026Oct 8, 2026Senior
Director, Commercial Data, Advanced Analytics & ForecastingRemoteSep 11, 2026Oct 8, 2026Senior
Market Development Director - Southeast RegionRemoteSep 4, 2026Oct 8, 2026Senior
Associate Director, Rare Disease Product MarketingRockville, MarylandAug 14, 2026Oct 8, 2026Senior
Senior Director, Global Program Development Lead - DMD/NeuromuscularRockville, MarylandJan 30, 2026Oct 8, 2026Senior
Senior Director/Director, Medical Science Liaisons (Neuromuscular/DMD)RemoteNov 6, 2025Oct 8, 2026Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Funding

Raised: $100.0M · Debt: $250.0M. Last 2 years.

Clinical trials (lead sponsor) 18

RecordTitlePhaseStatusStartPrimary completion
NCT04597385Long-term Follow-Up for RGX-121Not listedActive, not recruitingMar 14, 20212028-10 (estimated)
NCT05693142AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)Phase 2/Phase 3Active, not recruitingJan 4, 20232026-09 (estimated)
NCT05683379AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Males With DMDNot listedActive, not recruitingDec 20, 2022Jun 30, 2026 (actual)
NCT07652606Expanded Access to RGX-202Not listedTemporarily not availableNot listedNot listed
NCT07236606RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome)Phase 3Active, not recruitingNov 25, 2025Apr 30, 2028 (estimated)
NCT06103487Long Term Follow-Up for RGX-111Not listedEnrolling by invitationJul 24, 20232027-09 (estimated)
NCT06491927Long Term Follow-up for RGX-202Not listedEnrolling by invitationMay 8, 2024Dec 1, 2029 (estimated)
NCT03580083RGX-111 Gene Therapy in Patients With MPS IPhase 1/Phase 2SuspendedApr 3, 2019Jul 7, 2027 (estimated)
NCT04571970RGX-121 Gene Therapy in Children 5 Years of Age and Over With MPS II (Hunter Syndrome)Phase 1/Phase 2CompletedMar 11, 2021May 9, 2023 (actual)
NCT03566043CAMPSIITE™ RGX-121 Gene Therapy in Subjects With MPS II (Hunter Syndrome)Phase 2/Phase 3Active, not recruitingSep 27, 2018Nov 27, 2023 (actual)
NCT02651675A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH)Phase 1/Phase 2Terminated2016-03Nov 27, 2020 (actual)
NCT03066258Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD TrialPhase 1/Phase 2CompletedMar 29, 2017Nov 24, 2019 (actual)
NCT04080050A Long-term Follow-up Study to Evaluate the Safety and Efficacy of RGX-501Not listedUnknown status (ClinicalTrials.gov)Sep 30, 2019Sep 29, 2024 (estimated)
NCT04591834Mucopolysaccharidosis Type II ObservationalNot listedWithdrawn2022-032025-07 (estimated)
NCT03529786Mucopolysaccharidosis Type II Natural HistoryNot listedCompletedSep 27, 2017Mar 22, 2022 (actual)
NCT04462692An Observational Study in Children With CLN2 Batten DiseaseNot listedWithdrawnMar 31, 20212023-10 (estimated)
NCT04480476A Retrospective, Natural History Study in Children With CLN2Not listedWithdrawnMar 31, 20212022-04 (estimated)
NCT04148001Identifying and Genotyping Homozygous Familial Hypercholesterolemia (HoFH) PatientsNot listedCompletedDec 4, 2019Apr 8, 2020 (actual)

Connect

See your connections at REGENXBIO on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18

Feedback